Text Size

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00689117
First received: May 24, 2008
Last updated: September 22, 2011
Last verified: August 2011
History of Changes
Results First Received: November 2, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Acne Vulgaris
Acne
Interventions: Drug: CT Gel
Drug: Clindamycin Gel (clindamycin )
Drug: Tretinoin Gel (tretinoin)
Drug: Vehicle Gel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
CT Gel Clindamycin 1% as clindamycin phosphate and tretinoin 0.025% (CT) applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Clindamycin Gel Clindamycin phosphate 1% applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Tretinoin Gel Tretinoin 0.025% applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Vehicle Gel Topical application to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks

Participant Flow:   Overall Study
    CT Gel     Clindamycin Gel     Tretinoin Gel     Vehicle Gel  
STARTED     476     467     464     242  
COMPLETED     414     416     405     211  
NOT COMPLETED     62     51     59     31  
Adverse Event                 6                 0                 5                 0  
Lost to Follow-up                 26                 19                 17                 11  
Lack of Efficacy                 1                 2                 2                 2  
Non-Compliance with Study Treatment                 3                 3                 3                 1  
Withdrawal by Subject                 19                 18                 26                 13  
Unable to Comply with Visit Schedule                 0                 0                 1                 1  
Inclusion/Exclusion Criteria Not Met                 1                 2                 0                 0  
Non-compliance with Treatment Regimen                 0                 1                 0                 0  
Change/Discontinuation of Birth Control                 1                 1                 1                 0  
Use of Prohibitive Medication                 2                 1                 3                 0  
Pregnancy                 0                 2                 0                 2  
Incarceration                 2                 0                 0                 0  
Fear of Birth Defects                 0                 0                 1                 0  
Transportation                 1                 0                 0                 0  
Patient Withdrew from Study                 0                 0                 0                 1  
Personal Reason                 0                 1                 0                 0  
Dispensing Error                 0                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
CT Gel Clindamycin 1% as clindamycin phosphate and tretinoin 0.025% (CT) applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Clindamycin Gel Clindamycin phosphate 1% applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Tretinoin Gel Tretinoin 0.025% applied topically to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Vehicle Gel Topical application to the face (including forehead, nose, cheeks, and chin) once daily in the evening for 12 weeks
Total Total of all reporting groups

Baseline Measures
    CT Gel     Clindamycin Gel     Tretinoin Gel     Vehicle Gel     Total  
Number of Participants  
[units: participants]
 		  476     467     464     242     1649  
Age  
[units: years]
Mean ± Standard Deviation 		  20.8  ± 8.5     20.2  ± 8.1     20.2  ± 7.7     20.6  ± 8.4     20.4  ± 8.1  
Gender  
[units: participants]
 		         
Female     269     266     264     153     952  
Male     207     201     200     89     697  
Race/Ethnicity, Customized  
[units: participants]
 		         
American Indian or Alaska Native     4     4     4     3     15  
Asian     8     8     11     5     32  
Black     94     85     103     51     333  
Multiracial     12     16     19     5     52  
Native Hawaiian/Other Pacific Islander     0     4     2     1     7  
White     358     349     324     176     1207  
Missing     0     1     1     1     3  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study)   [ Time Frame: Baseline, Week 12 ]
  Show Outcome Measure 1

2.  Primary:   The Percentage of Participants Who Had a Minimum 2-grade Improvement in the Investigator’s Static Global Assessment (ISGA) Score From Baseline to Week 12   [ Time Frame: Baseline, Week 12 ]
  Show Outcome Measure 2

3.  Secondary:   Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12   [ Time Frame: Baseline, Week 12 ]
  Show Outcome Measure 3

4.  Secondary:   The Percentage of Participants With a Subjects Global Assessment Score of 0 or 1 at Week 12   [ Time Frame: Week 12 ]
  Show Outcome Measure 4

5.  Secondary:   The Percentage of Participants Who Had ISGA Scores of 0 or 1 at Week 12   [ Time Frame: Week 12 ]
  Show Outcome Measure 5


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided


Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00689117     History of Changes
Other Study ID Numbers: 114681, W0265-03
Study First Received: May 24, 2008
Results First Received: November 2, 2010
Last Updated: September 22, 2011
Health Authority: Canada: Health Canada
United States: Food and Drug Administration